A long-awaited update from Amgen’s Kras inhibitor shows waning single-agent efficacy – a situation apparently pre-empted by Mirati.
Licensing deal could enable bundling of antipsychotics with management technology.
A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.
In Dapa-CKD, Farxiga-treated patients without diabetes did numerically better than those with diabetes.
A similar benefit suggests a class effect with the SGLT2s in heart failure, leaving Lilly and Boehringer playing catch-up to Astra.
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?